<article article-type="other"> 
 <!--?properties open_acces=""?--> 
 <!-- Original-type: gg--> 
 <front> 
  <journal-meta> 
   <journal-id journal-id-type="nlm-ta">
     Br J Cancer 
   </journal-id> 
   <journal-h3>
     British Journal of Cancer 
   </journal-h3> 
   <issn pub-type="ppub">
     0007-0920 
   </issn> 
   <issn pub-type="epub">
     1532-1827 
   </issn> 
   <publisher> 
    <publisher-name>
      Nature Publishing Group 
    </publisher-name> 
   </publisher> 
  </journal-meta> 
  <article-meta> 
   <article-id pub-id-type="pmid">
     16969349 
   </article-id> 
   <article-id pub-id-type="pmc">
     2360724 
   </article-id> 
   <article-id pub-id-type="pii">
     6603337 
   </article-id> 
   <article-id pub-id-type="doi">
     10.1038/sj.bjc.6603337 
   </article-id> 
   <article-categories> 
    <subj-group subj-group-type="heading"> 
     <subject>
       Genetics and Genomics 
     </subject> 
    </subj-group> 
   </article-categories> 
   <h3-group> 
    <article-h3>
      Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer 
    </article-h3> 
   </h3-group> 
   <contrib-group> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Miranda 
      </surname> 
      <given-names>
        E 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Destro 
      </surname> 
      <given-names>
        A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Malesci 
      </surname> 
      <given-names>
        A 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff2">
       2 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Balladore 
      </surname> 
      <given-names>
        E 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Bianchi 
      </surname> 
      <given-names>
        P 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Baryshnikova 
      </surname> 
      <given-names>
        E 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Franchi 
      </surname> 
      <given-names>
        G 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Morenghi 
      </surname> 
      <given-names>
        E 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff3">
       3 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Laghi 
      </surname> 
      <given-names>
        L 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="aff" rid="aff4">
       4 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Gennari 
      </surname> 
      <given-names>
        L 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff5">
       5 
     </xref> 
    </contrib> 
    <contrib contrib-type="author"> 
     <name> 
      <surname>
        Roncalli 
      </surname> 
      <given-names>
        M 
      </given-names> 
     </name> 
     <xref ref-type="aff" rid="aff1">
       1 
     </xref> 
     <xref ref-type="aff" rid="aff6">
       6 
     </xref> 
     <xref ref-type="corresp" rid="caf1">
       * 
     </xref> 
    </contrib> 
   </contrib-group> 
   <aff id="aff1"> 
    <label>1</label> 
    <institution>
      Molecular Genetics Laboratory, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <aff id="aff2"> 
    <label>2</label> 
    <institution>
      Departement of Gastroenterology, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <aff id="aff3"> 
    <label>3</label> 
    <institution>
      Clinical Trial Office, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <aff id="aff4"> 
    <label>4</label> 
    <institution>
      Departement of Gastroenterology, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <aff id="aff5"> 
    <label>5</label> 
    <institution>
      Departement of Surgery, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <aff id="aff6"> 
    <label>6</label> 
    <institution>
      Departement of Pathology, Istituto Clinico Humanitas, University of Milan 
    </institution> Via Manzoni 56, Rozzano, Milano 20089, 
    <country>
      Italy 
    </country> 
   </aff> 
   <author-notes> 
    <corresp id="caf1"> 
     <label>*</label>Author for correspondence: 
     <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:massimo.roncalli@unimi.it">
       massimo.roncalli@unimi.it 
     </email> 
    </corresp> 
   </author-notes> 
   <pub-date pub-type="epub"> 
    <day>
      12 
    </day> 
    <month>
      09 
    </month> 
    <year>
      2006 
    </year> 
   </pub-date> 
   <pub-date pub-type="collection"> 
    <day>
      17 
    </day> 
    <month>
      10 
    </month> 
    <year>
      2006 
    </year> 
   </pub-date> 
   <pub-date pub-type="ppub"> 
    <day>
      23 
    </day> 
    <month>
      10 
    </month> 
    <year>
      2006 
    </year> 
   </pub-date> 
   <volume>
     95 
   </volume> 
   <issue>
     8 
   </issue> 
   <fpage>
     1101 
   </fpage> 
   <lpage>
     1107 
   </lpage> 
   <history> 
    <date date-type="received"> 
     <day>
       12 
     </day> 
     <month>
       04 
     </month> 
     <year>
       2006 
     </year> 
    </date> 
    <date date-type="rev-recd"> 
     <day>
       25 
     </day> 
     <month>
       07 
     </month> 
     <year>
       2006 
     </year> 
    </date> 
    <date date-type="accepted"> 
     <day>
       31 
     </day> 
     <month>
       07 
     </month> 
     <year>
       2006 
     </year> 
    </date> 
   </history> 
   <copyright-statement>
     Copyright 2006, Cancer Research UK 
   </copyright-statement> 
   <copyright-year>
     2006 
   </copyright-year> 
   <permissions> 
    <copyright-holder>
      Cancer Research UK 
    </copyright-holder> 
   </permissions> 
   <abstract> 
    <h3>Abstract</h3> 
    <p>Colorectal cancer (CRC) develops as multistep process, which involves genetic and epigenetic alterations. 
     <italic>
       K-Ras 
     </italic>, 
     <italic>
       p53 
     </italic> and 
     <italic>
       B-Raf 
     </italic> mutations and 
     <italic>
       RASSF1A 
     </italic>, 
     <italic>
       E-Cadherin 
     </italic> and 
     <italic>
       p16INK4A 
     </italic> promoter methylation were investigated in 202 CRCs with and without lymph node and/or liver metastasis, to assess whether gene abnormalities are related to a metastogenic phenotype. 
     <italic>
       K-Ras 
     </italic>, 
     <italic>
       B-Raf 
     </italic> and 
     <italic>
       p53 
     </italic> mutations were detected in 27, 3 and 32% of the cases, with 
     <italic>
       K-Ras 
     </italic> mutations significantly associated with metastatic tumour ( 
     <italic>
       P 
     </italic>=0.019). 
     <italic>
       RASSF1A 
     </italic>, 
     <italic>
       E-Cadherin 
     </italic> and 
     <italic>
       p16INK4A 
     </italic> methylation was documented in 20, 44 and 33% of the cases with 
     <italic>
       p16INK4A 
     </italic> significantly associated with metastatic tumours ( 
     <italic>
       P 
     </italic>=0.001). Overall, out of 202 tumours, 34 (17%) did not show any molecular change, 125 (62%) had one or two and 43 (21%) three or more. Primary but yet metastatic CRCs were prevalent in the latter group ( 
     <italic>
       P 
     </italic>=0.023) where the most frequent combination was one genetic (K-Ras in particular) and two epigenetic alterations. In conclusion, this analysis provided to detect some molecular differences between primary metastatic and nonmetastatic CRCs, with 
     <italic>
       K-Ras 
     </italic> and 
     <italic>
       p16INK4A 
     </italic> statistically altered in metastatic tumours; particular gene combinations, such as coincidental 
     <italic>
       K-Ras 
     </italic> mutation with two methylated genes are associated to a metastogenic phenotype.</p> 
   </abstract> 
   <kwd-group> 
    <kwd>
      colorectal cancer 
    </kwd> 
    <kwd>
      genetic and epigenetic alterations 
    </kwd> 
    <kwd>
      metastogenic phenotype 
    </kwd> 
   </kwd-group> 
  </article-meta> 
 </front> 
 <p>Colorectal cancer (CRC) is one of the most common malignant neoplasm worldwide. The prognosis is significantly affected by the tumour stage that mainly rests on the ability to metastasise to lymph nodes and/or to the liver. Indeed, the 5-year-survival is over 90% for Duke's stage A, but only 5% for Duke's stage D ( 
  <xref ref-type="other" rid="bib8">
    de la Chapelle, 2004 
  </xref>). Sequential and additional genetic alterations affecting several proto-oncogenes and tumour suppressor genes have been recognised in the pathogenesis of CRC. Less known are the molecular events responsible for the progression and metastatisation of CRC; it is reasonable that the molecular profile of primary but yet metastatic CRC may be helpful to understand the molecular basis of extracolic tumour spread and to define therapeutic strategies against ?metastogenic' genes. Previous studies targeted to ascertain the molecular progression of CRC investigated genetic abnormalities of proto-oncogenes ( 
  <italic>
    K-Ras 
  </italic>) and tumour suppressor genes ( 
  <italic>
    p53 
  </italic> and 
  <italic>
    APC 
  </italic>) or, alternatively, molecular epigenetic changes ( 
  <italic>
    E-Cadherin 
  </italic>, 
  <italic>
    p16INK4A 
  </italic>, 
  <italic>
    DAPK, RASSF1A 
  </italic> and 
  <italic>
    APC 
  </italic>) ( 
  <xref ref-type="other" rid="bib30">
    Smith 
   <italic>
     et al 
   </italic>, 2002 
  </xref>; 
  <xref ref-type="other" rid="bib20">
    Lee 
   <italic>
     et al 
   </italic>, 2004 
  </xref>). The present study was aimed to investigate both genetic and epigenetic changes occurring in CRC by comparing the molecular profiles of primary metastatic and nonmetastatic tumours. We selected for study the mutational status of 
  <italic>
    K-Ras 
  </italic>, 
  <italic>
    B-Raf 
  </italic> and 
  <italic>
    p53 
  </italic> and the epigenetic status of 
  <italic>
    RASSF1A 
  </italic>, 
  <italic>
    E-Cadherin 
  </italic> and 
  <italic>
    p16INK4A 
  </italic>.</p> 
 <p>Abnormalities of 
  <italic>
    K-Ras 
  </italic> are key events in colorectal carcinogenesis and mutations of the gene arise early during the colonic transformation in 20?50% of the tumours ( 
  <xref ref-type="other" rid="bib2">
    Bazan 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). 
  <italic>
    K-Ras 
  </italic> has been also implicated in the process of tumour invasion and metastasis ( 
  <xref ref-type="other" rid="bib11">
    Giehl, 2005 
  </xref>). Mutations that prevalently occur at codon 12, prevent efficient GTP-hydrolysis and thus render the protein in an activated state. As a result, multiple Ras effector pathways, which control fundamental biological processes such as proliferation, apoptosis and cell motility become constitutively activated and/or deregulated ( 
  <xref ref-type="other" rid="bib24">
    Pollock 
   <italic>
     et al 
   </italic>, 2005 
  </xref>). The best characterised Ras effectors are the Raf serine/threonine kinases ( 
  <italic>
    A-Raf 
  </italic>, 
  <italic>
    B-Raf 
  </italic> and 
  <italic>
    Raf-1 
  </italic>) that upregulate the MAP kinase cascade ( 
  <xref ref-type="other" rid="bib19">
    Kolch, 2000 
  </xref>). 
  <xref ref-type="other" rid="bib7">
    Davies 
   <italic>
     et al 
   </italic> (2002) 
  </xref> recently reported that 
  <italic>
    B-Raf 
  </italic> mutations play a pivotal role in the oncogenesis of melanoma and colorectal carcinoma. The majority of analysed samples exhibited one specific 
  <italic>
    B-Raf 
  </italic> alteration that caused the exchange of valine to glutamate, a negatively charged amino acid, at position 599 (V599E) in the kinase domain of the protein. Interestingly, it has been shown that this alteration causes the growth of carcinoma cell lines independent from Ras activation.</p> 
 <p>The 
  <italic>
    p53 
  </italic> suppressor gene encodes a nuclear phosphoprotein that regulates cell cycle and apoptosis. Mutations in this gene constitute some of the most frequently occurring genetic changes at human malignancies and are thought to be late development in the adenoma?carcinoma sequence in CRC ( 
  <xref ref-type="other" rid="bib9">
    Fearon and Vogelstein, 1990 
  </xref>). Mutations in this gene increase the protein half-life and are often associated with protein overexpression in the nucleus ( 
  <xref ref-type="other" rid="bib26">
    Remvikos 
   <italic>
     et al 
   </italic>, 1990 
  </xref>). Mutations most commonly occur in the highly conserved region (exons 5?8), which encodes the DNA-binding domain ( 
  <xref ref-type="other" rid="bib37">
    Zhang 
   <italic>
     et al 
   </italic>, 1997 
  </xref>).</p> 
 <p>During the last decade, epigenetic changes have been reported in many cancers and they are now recognised to be at least as common as genetic changes. Hypermethylation of selected CpG sites within CpG islands in the promoter region of tumour suppressor genes is associated with loss of gene expression and is observed in both physiological conditions and neoplasia ( 
  <xref ref-type="other" rid="bib18">
    Kim 
   <italic>
     et al 
   </italic>, 2005b 
  </xref>). By inactivating various tumour suppressor genes, this epigenetic modification can affect many important cellular processes, such as cell proliferation, apoptosis, invasion and metastasis.</p> 
 <p>RASSF1 proteins are potential Ras effectors and the major isoform, 
  <italic>
    RASSF1A 
  </italic>, is an important human tumour suppressor protein acting at G1/S phase of cell-cycle progression ( 
  <xref ref-type="other" rid="bib5">
    Dammann 
   <italic>
     et al 
   </italic>, 2003 
  </xref>). This protein can induce cycle arrest by cyclin D1 inhibition. The 
  <italic>
    RASSF1A 
  </italic> locus at 3p21.3 is methylated at high frequency in a variety of solid tumours including CRC, where this gene has been analysed as an alternative marker to downregulate Ras pathway ( 
  <xref ref-type="other" rid="bib23">
    Pizzi 
   <italic>
     et al 
   </italic>, 2005 
  </xref>).</p> 
 <p> 
  <italic>
    E-Cadherin 
  </italic> belongs to a family of Ca<sup>2+</sup>-dependent adhesion molecules that mediate intercellular contacts critical to morphogenesis and the maintenance of tissue structure ( 
  <xref ref-type="other" rid="bib31">
    Takeichi, 1995 
  </xref>). Reduced expression of E-Cadherin owing to aberrant CpG island hypermethylation has been regarded as one of the main molecular events involved in the dysfunction of the cell?cell adhesion system ( 
  <xref ref-type="other" rid="bib6">
    Darwanto 
   <italic>
     et al 
   </italic>, 2003 
  </xref>), in invasion and metastasis ( 
  <xref ref-type="other" rid="bib10">
    Garinis 
   <italic>
     et al 
   </italic>, 2002 
  </xref>). Recently, it has been shown that loss of E-Cadherin expression in a transgenic mouse model is associated with the development of invasive colorectal carcinoma from well-differentiated adenomas ( 
  <xref ref-type="other" rid="bib34">
    Wheeler 
   <italic>
     et al 
   </italic>, 2001 
  </xref>).</p> 
 <p> 
  <italic>
    p16INK4A 
  </italic> gene is one of the most frequently inactivated tumour suppressor genes in human cancer ( 
  <xref ref-type="other" rid="bib16">
    Kamb 
   <italic>
     et al 
   </italic>, 1994 
  </xref>). The 
  <italic>
    p16INK4A 
  </italic> product, an inhibitor of cyclin-dependent kinases 4 and 6, is capable of preventing Rb phosphorylation, thus blocking cells in the G1 phase of the cell cycle ( 
  <xref ref-type="other" rid="bib28">
    Serrano 
   <italic>
     et al 
   </italic>, 1996 
  </xref>). It is known that 
  <italic>
    p16INK4A 
  </italic> expression in colon cancer cells is repressed by methylation at the CpG island of promoter, but 
  <italic>
    in vivo 
  </italic> silencing of 
  <italic>
    p16INK4A 
  </italic> methylation has not been widely investigated ( 
  <xref ref-type="other" rid="bib17">
    Kim 
   <italic>
     et al 
   </italic>, 2005a 
  </xref>).</p> 
 <p>We designed a study aimed to compare genetic and epigenetic changes occurring in primary advanced nonmetastatic CRCs as opposed to primary advanced metastatic CRCs. The target was to establish in CRCs if and which genetic and epigenetic molecular abnormalities, among a number of selected genes, are associated to a metastogenic phenotype.</p> 
 <sec sec-type="materials|methods"> 
  <h3>MATERIALS AND METHODS</h3> 
  <sec> 
   <h3>Patients</h3> 
   <p><span style="background-color:#ffecec">This study includes 202 consecutive primary advanced metastatic and nonmetastatic CRCs surgically removed from 1997 to 2002</span>. <span style="background-color:#ffcccc">Table 1 reports the main clinico-pathological features of the series</span>. <span style="background-color:#fff5f5">We elected to study and to compare two homogeneous groups of CRC cases, namely those invading through muscolaris mucosa into subsierosa (or into nonperitonealised pericolic or perirectal tissues) with and without lymph nodes and/or liver metastases</span>. <span style="background-color:#ffdada">In such a way, the only significant morphological and biological variable between the two groups was the presence of metastatic deposits</span>. <span style="background-color:#ffffff">Accordingly, these two groups will be referred to throughout the paper as metastatic (M+) and nonmetastatic (M?) tumours</span>.</p> 
  </sec> 
  <sec> 
   <h3>DNA extraction</h3> 
   <p><span style="background-color:#ffffff">Samples were fixed in formalin and embedded in paraffin</span>. <span style="background-color:#ffffff">Paraffin blocks were cut into several 2? ? m sections</span>. <span style="background-color:#ffffff">One section from each tissue was stained with hematoxylin?eosin to distinguish neoplastic tissue from the nonmalignant counterpart</span>. <span style="background-color:#ffffff">After manual dissection, DNA was extracted from the unstained section of the malignant tissue as described previously ( Roncalli et al , 2002 )</span>. <span style="background-color:#ffffff">Briefly, tissue sections were deparaffinised using 100% xylene (Sigma, Saint Louis, MO, USA) followed by 100% ethanol</span>. <span style="background-color:#ffffff">The pellet was then resuspended in a buffer containing proteinase K (Finnzyme, Espoo, Finland), and DNA was extracted with phenol?chloroform (Sigma, Saint Louis, MO, USA) followed by ethanol precipitation</span>. <span style="background-color:#ffffff">Finally, precipitated DNA was resuspended in 100? ? l of water</span>. <span style="background-color:#fff7f7">DNA was quantified spectrophotometrically, and 200?ng were used as a template for each PCR amplification</span>.</p> 
  </sec> 
  <sec> 
   <h3> 
    <italic>
      K-Ras 
    </italic> and 
    <italic>
      B-Raf 
    </italic> mutation (PCR?RFLP)</h3> 
   <p><span style="background-color:#ffd2d2">Mutations at codon 12 of the K-Ras gene and at codon 599 of the B-Raf gene were detected by PCR?RFLP that identifies codon 12 and 599 mutations but not the specifically altered nucleotide</span>. <span style="background-color:#ffe5e5">K-Ras codon 12 mutations were detected using the Bst NI restriction enzymes (New England Biolabs Inc., Beverly, MA, USA)</span>. <span style="background-color:#fff7f7">Briefly, 200?ng of DNA were used as template for the first PCR, which consisted of a 50? ? l volume containing Taq DNA polymerase (1?U; Finnzyme, Espoo, Finland), deoxynucleotide triphosphates (0.2?m M ; Finnzyme, Espoo, Finland), reaction buffer (5? ? l; Finnzyme, Espoo, Finland), the primers forward (0.2?pmol? ? l?1; Proligo, Boulder, CO, USA): 5?-ACTGAATATAAACTTGTGGTAGTTGGACCT-3? and reverse (0.2?pmol? ? l?1; Proligo, Boulder, CO, USA): 5?-TCAAAAGAATGGTCCTGCACCAG-3?</span>. <span style="background-color:#fff2f2">The forward primer creates the restriction site for Bst NI, which is lost when K-Ras is mutated at codon 12</span></p> 
   <p><span style="background-color:#fff8f8">For amplification, a DNA thermocycler (MBS 0.2S, Hybaid, Ashford, UK) was used</span>. <span style="background-color:#ffffff">Cycling conditions of the first PCR were as follows: initial denaturation (4?min at 94?C), followed by 40 cycles of denaturation (30?s at 94?C), annealing (15?s at 53?C), and elongation (30?s at 72?C)</span>. <span style="background-color:#ffffff">An elongation of 10?min at 72?C followed the last cycle; at the end, samples were kept at 4?C</span>. <span style="background-color:#fff8f8">Twenty microlitres of the PCR reaction were then digested with Bst NI for 4?h at 60?C in a total volume of 50? ? l</span>. <span style="background-color:#ffe4e4">When codon 12 is wild-type, the PCR product contains a restriction site for Bst NI, and digestion yields bands of 128 and 29?bp</span>. <span style="background-color:#ffdbdb">If there is a mutation in either of the first two bases of codon 12, the mutant PCR fragment will not be cut and will remain at its original size of 157?bp</span>. <span style="background-color:#ffffff">Digested products were visualised by electrophoresis on a 3% agarose gels (containing 0.5? ? g?ml?1 ethidium bromide)</span>. <span style="background-color:#ffe8e8">Positive (SW480 cell line) and negative controls (Human Placental DNA) for the mutation and controls for carryover DNA contamination were included in every experiment</span>. <span style="background-color:#ffecec">B-Raf V599E mutations were analysed first by amplification using primers forward (0.2?pmol? ? l?1; Proligo, Boulder, CO, USA): 5?-CTGTTTTCCTTTACTTACTACACCTCAGATA-3? and reverse (0.2?pmol? ? l?1; Proligo, Boulder, CO, USA): 5?-CTCAATTCTTACCATCCACAAAATG-3?</span>. <span style="background-color:#fff0f0">After 40 cycles of amplification (annealing temperature 55?C), amplified DNA was subjected to Tsp RI (New England Biolabs, Beverly, MA, USA) restriction digestion because this mutation abrogates a restriction site present in the wild-type sequence</span>. <span style="background-color:#ffffff">After incubation with the enzyme at 65?C overnight, the products were analysed on 3% agarose gels</span>. <span style="background-color:#ffffff">Special care was taken to directly load the samples at high temperature (70?C) and in the presence of formamide (0.2%) to avoid reannealing of the restricted products ( Tsp RI leaves a nine-base 3? overhang)</span>. <span style="background-color:#ffffff">DNA containing the wild-type (Human Placental DNA) or the mutated T1976 sequence (HT29 cell line) was always included as controls</span>.</p> 
  </sec> 
  <sec> 
   <h3> 
    <italic>
      P53 
    </italic> mutation</h3> 
   <p><span style="background-color:#ffffff">We used both SSCP and immunohistochemistry</span>.</p> 
   <sec> 
    <h3>SSCP</h3> 
    <p><span style="background-color:#ffe6e6">By SSCP we identified samples with altered p53 migratory pattern, by gene mutation or polymorphism</span>. <span style="background-color:#ffffff">Briefly, PCR fragments were generated from 200?ng of genomic DNA in a 50? ? l PCR reaction buffer</span>. <span style="background-color:#ffc4c4">The primers (0.4?pmol? ? l?1; Proligo, Boulder, CO, USA) and the condition for PCR are described in the Table 1 of Supplementary Appendix available on the BJC website</span>. <span style="background-color:#fff6f6">DNA containing the wild-type p53 (Human Placental DNA) was always included as controls</span>. <span style="background-color:#fff7f7">For SSCP analysis, PCR product was mixed with an equal volume of loading buffer containing 100% formamide (Sigma, Saint Louis, MO, USA), 0.05% xylene cyanol (Sigma, Saint Louis, MO, USA), and 0.05% bromphenol blue (Amersham Bioscience Corporation, Buckinghamshire, UK); heated at 96?C for 10?min and put on ice before being loaded on 37.5% TBE polyacrylamide gels and electrophoresed for 1?h at 100?V and 4?5?h at 300?V</span>. <span style="background-color:#ffffff">The gels were silver stained with DNA Silver Staining Kit (Amersham Bioscience Corporation, Buckinghamshire, UK) according to the manufacturer's recommendations</span>.</p> 
   </sec> 
   <sec> 
    <h3>Immunohistochemistry</h3> 
    <p><span style="background-color:#ffeded">To analyse p53 expression, formalin-fixed paraffin-embedded tissue sections (2? ? m) were used, deparaffinised and exposed to an antigen retrieval system (1?m M EDTA, pH 8, and 98?C for 30?min) before being incubated with the specific p53 antibody (1:1000, Ab-2, Calbiochem; Oncogene Research Products, Cambridge, MA, USA)</span>. <span style="background-color:#fff8f8">Endogenous peroxidase was blocked with 3% hydrogen peroxide for 20?min at room temperature</span>. <span style="background-color:#fff8f8">Primary mouse monoclonal antibody was applied for 1?h at room temperature</span>. <span style="background-color:#fff8f8">Reactive sites were identified with secondary antibody (HRP rabbit/mouse, ChemMate DAKO Envision, Carpinteria, CA, USA) for 30?min at room temperature</span>. <span style="background-color:#ffffff">Immunoperoxidase staining, using diaminobenzidine as chromogen, was carried out (DAB+chromogen X-50, ChemMate, DAKOCytomation, Carpinteria, CA, USA)</span>. <span style="background-color:#ffffff">The slides were counterstained with hematoxylin (Harris Hematoxylin, DiaPath, Microstain Division, Martinengo, BG, Italy)</span>. <span style="background-color:#ffecec">An abnormal SSCP pattern coincidental with p53 nuclear immunoreactivity was taken as indicative of cases with p53 mutation</span>. <span style="background-color:#ffffff">Indeed, an altered SSCP pattern may be merely related to gene polymorphism and as such being not indicative of an abnormally mutated gene</span>. <span style="background-color:#ffe6e6">On the other hand, the mere immunocytochemical detection of p53 gene product may also be due to an increased protein stabilisation uncoupled from mutation ( Cripps et al , 1994 )</span>. <span style="background-color:#fff5f5">Therefore, the less expensive, quick and efficient way to detect p53 mutations is to associate an abnormal SSCP pattern with the nuclear immunocytochemical detection of the gene product</span>.</p> 
   </sec> 
  </sec> 
  <sec> 
   <h3> 
    <italic>
      RASSF1A 
    </italic>, E- Cadherin and 
    <italic>
      p16INK4A 
    </italic> methylation</h3> 
   <p><span style="background-color:#ffcbcb">As previously reported ( Roncalli et al , 2002 ), 1? ? g of genomic DNA in a volume of 50? ? l was denatured by NaOH for 10?min at 37?C; 30? ? l of 10?m M hydroquinone (Sigma, Saint Louis, MO, USA) and 520? ? l of 3? M sodium bisulphite (Sigma, Saint Louis, MO, USA) at pH 5, both freshly prepared, were added and mixed, and samples were incubated at 50?C for 16?h</span>. <span style="background-color:#ffffff">Modified DNA was purified using the Wizard DNA purification resin according to the manufacturer's instruction (Promega, Milano, Italy) and eluted into 50? ? l of water</span>. <span style="background-color:#fff8f8">Modification was completed by NaOH treatment (final concentration 0.3? M ) for 5?min at room temperature, followed by ethanol precipitation</span>. <span style="background-color:#ffffff">DNA was resuspended in water and used immediately or stored at ?20?C</span>. <span style="background-color:#ffc4c4">Polymerase chain reaction was performed separately with methylation-specific primers (0.12?pmol? ? l?1; Proligo, Boulder, CO, USA) and unmethylation primers (0.12?pmol? ? l?1; Proligo, Boulder, CO, USA) for each gene ( Supplementary Appendix, Table 1 )</span>. <span style="background-color:#fff7f7">Unmethylated (Human Placental DNA) and methylated DNA (LoVo, COLO320 and HepG2 cell lines for RASSF1A, E-Cadherin and p16INK4A , respectively) were used as MSP controls</span>. <span style="background-color:#ffffff">Polymerase chain reaction products were analysed on 2% agarose gels, stained with ethidium bromide (0.5? ? g?ml?1), and visualised under UV illumination</span>. <span style="background-color:#ffffff">A sample was classified as methylated whenever a band, corresponding to the molecular weight of the methylated PCR product, had a thickness and staining intensity equal or greater than that of the unmethylated PCR product</span>. <span style="background-color:#ffe4e4">Figure 1 of Supplementary Appendix available on the BJC website illustrates an example of methylated and unmethylated PCR products</span></p> 
  </sec> 
  <sec> 
   <h3>Statistical analyses</h3> 
   <p><span style="background-color:#ffffff">Data were described as number and percentage or means and s.d., whether appropriate</span>. <span style="background-color:#ffa6a6">Differences in frequencies of variables were tested using the ? 2 test (Pearson or Fisher, if appropriate), and differences in mean levels of variables were tested using the t -test</span>. <span style="background-color:#fff8f8">A P -value of 0.05 was considered statistically significant</span>. <span style="background-color:#ffdbdb">All variables found to have a P -value ?0.1 in the univariate evaluation were considered to be candidates for a subsequent stepwise multivariate logistic regression analysis</span>. <span style="background-color:#ffffff">Data analysis was performed using STATA9</span>.</p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>RESULTS</h3> 
  <sec> 
   <h3>Genetic changes</h3> 
   <p><span style="background-color:#ff6060">The mutational status of K-Ras , B-Raf and p53 in 202 cases of CRC is shown in Table 2a </span></p> 
   <sec> 
    <h3> 
     <italic>
       K-Ras 
     </italic> </h3> 
    <p><span style="background-color:#ffafaf">Codon 12 K-Ras mutations were found in 54 cases (27%)</span>. <span style="background-color:#ffc2c2">By univariate analysis, K-Ras mutations were significantly associated with M+ tumours ( P =0.016) and more frequent detectable in the right side ( P =0.088)</span>. <span style="background-color:#ffe6e6">Multivariate analysis confirmed the association between K-Ras mutations and M+ tumours (OR 2.37, 95% CI, 1.15?4.88, P =0.019)</span></p> 
   </sec> 
   <sec> 
    <h3> 
     <italic>
       B-Raf 
     </italic> </h3> 
    <p><span style="background-color:#ffa1a1">Seven cases (3%) showed B-Raf mutation but none of these had a coincidental mutation in the K-Ras gene nor a statistical association with the other clinico-pathological variables</span></p> 
   </sec> 
   <sec> 
    <h3> 
     <italic>
       p53 
     </italic> </h3> 
    <p><span style="background-color:#ffe3e3">An altered SSCP pattern was identified in 91 (45%) out of 202 samples, whereas p53 nuclear immunoreactivity was detected in 115 (57%) out of 202 cases</span>. <span style="background-color:#ff8a8a">A coincidental abnormal SSCP migratory pattern and p53 nuclear immunoreactivity was documented in 65 (32%) out of 202 cases</span>.</p> 
    <p><span style="background-color:#ffc0c0">No association was found in cases showing both genetic and phenotypic p53 abnormalities with the clinico-pathological parameters under study</span></p> 
   </sec> 
  </sec> 
  <sec> 
   <h3>Epigenetic changes</h3> 
   <p><span style="background-color:#ffc0c0">All cases showing PCR products for methylated DNA sequences also exhibited unmethylated DNA sequences, which was related to tumour heterogeneity or to the occurrence of intermingled non-neoplastic cells</span>. <span style="background-color:#ffcbcb">The epigenetic profile of RASSF1A , E-Cadherin and p16INK4A in CRC is shown in Table 2b </span></p> 
   <sec> 
    <h3> 
     <italic>
       RASSF1A 
     </italic> </h3> 
    <p><span style="background-color:#ffdbdb">Out of 202 tumours, RASSF1A was methylated in 40 (20%) tumours, the majority occurring in M+ tumours ( P =0.021)</span>. <span style="background-color:#ffe7e7">No other association was found between RASSF1A methylation and the clinico-pathological parameters under study</span></p> 
   </sec> 
   <sec> 
    <h3> 
     <italic>
       E-Cadherin 
     </italic> </h3> 
    <p><span style="background-color:#ffe3e3">Out of 202 cases, E-Cadherin methylation was detected in 88 (44%) cases</span>. <span style="background-color:#ffd3d3">E-Cadherin methylation was more frequently detectable in the right colon ( P =0.011) and in older patients ( P =0.002)</span>. <span style="background-color:#fff8f8">E-Cadherin methylation was also associated with RASSF1A methylation ( P =0.047)</span>. <span style="background-color:#ffe2e2">All these variables retained a statistical significance in multivariate analysis (right side: OR 0.59, 95% CI, 0.40?0.87, P =0.007; older age: OR 1.039, 95% CI, 1.01?1.07, P =0.004; RASSF1A methylation: OR 2.11, 95% CI, 1.01?4.41, P =0.047)</span></p> 
   </sec> 
   <sec> 
    <h3> 
     <italic>
       p16INK4A 
     </italic> </h3> 
    <p><span style="background-color:#ffb7b7">Out of 202 cases, p16INK4A promoter methylation was found in 67 (33%) cases</span>. <span style="background-color:#ffeded">p16INK4A methylation was significantly associated with M+ tumours ( P &lt;0.001)</span>. <span style="background-color:#ffe5e5">p16INK4A methylation was associated with B-Raf mutations ( P &lt;0.001), RASSF1A ( P =0.004) and E-Cadherin ( P =0.040) methylation</span>. <span style="background-color:#ffe4e4">p16INK4A methylation was more frequently detectable in p53 mutated cases ( P =0.075)</span>. <span style="background-color:#ffecec">Multivariate analysis showed that gene methylation was statistically associated with M+ tumours (OR 3.48, 95% CI, 1.66?7.26, P =0.001) and with RASSF1A methylation (OR 2.29, 95% CI, 1.07?4.89, P =0.032)</span></p> 
   </sec> 
  </sec> 
  <sec> 
   <h3>Coincidental genetic and epigenetic changes</h3> 
   <p><span style="background-color:#ffa8a8">Out of 202 CRCs, thirty-four (17%) were free from molecular abnormalities and with no association with M+ vs M? tumours</span>. <span style="background-color:#ffc8c8">Regardless the type of molecular abnormalities, 68 cases (34%) showed one molecular alteration, 57 cases (28%) two molecular alterations and 43 cases (21%) ?3 molecular alterations</span>. <span style="background-color:#ffe7e7">No statistical association was seen between M+ and M? CRCs showing one or two gene alterations</span>. <span style="background-color:#ffeded">Conversely, the frequency of CRCs in the group showing three or more alterations was higher in M+ than in M? tumours (34/130=26% vs 9/72=12%; P =0.023)</span>. <span style="background-color:#ffe6e6">In the latter (?3 abnormalities) group, the most frequent combination of genes was one genetic and two epigenetic alterations, particularly K-Ras mutations (18/34=53%), with gene methylation equally affecting the three genes under study ( RASSF1A , E-Cadherin and p16INK4A )</span>. <span style="background-color:#ffaeae">Coincidental methylation of these genes was also documented in 12 cases, 11 of whose were M+ CRCs ( P =0.042)</span></p> 
  </sec> 
  <sec> 
   <h3>Multivariate analysis of variables associated with M+ tumours</h3> 
   <p><span style="background-color:#ffa2a2">Among the variables associated with M+ cancers in univariate analysis ( K-Ras mutation, p16INK4A methylation, RASSF1A methylation, younger age and grading), multivariate analysis showed that only K-Ras mutations (OR 2.98, 95% CI, 1.37?6.46, P =0.006), p16INK4A methylation (OR 4.58, 95% CI, 2.14?9.76, P &lt;0.001) and younger age (OR 0.95, 95% CI, 0.92?0.98, P &lt;0.001) retained a statistically significant value</span></p> 
  </sec> 
 </sec> 
 <sec> 
  <h3>DISCUSSION</h3> 
  <p><span style="background-color:#ffecec">Aim of this study was to characterise genetic and epigenetic molecular alterations occurring in primary advanced M+ and M? CRCs</span>.</p> 
  <p><span style="background-color:#ffa8a8">The model of CRC relies upon the sequential accumulation of genetic and epigenetic changes but, in our study, 17% of cases had no abnormalities in the investigated genes ( K-Ras , B-Raf , p53 , RASSF1A , E-Cadherin , p16INK4A )</span>. <span style="background-color:#ffffff">These data are in agreement with previous studies examining different sets of genes</span>. <span style="background-color:#ffe4e4">Smith et al (2002) investigated K-Ras , p53 and APC in 106 cases and 10% CRC were reported free of molecular abnormalities</span>. <span style="background-color:#ffebeb">Lee et al (2004) examined promoter methylation of 12 different genes in 149 CRCs and found that 9% were unmethylated</span>. <span style="background-color:#ffeeee">Chiang et al (2004) also demonstrated that the three key mutations (APC, K-Ras and p53 ) are rarely coincidental in 122 sporadic CRCs</span>. <span style="background-color:#ffcaca">All these findings suggest that alterations in the genes mostly involved in colorectal carcinogenesis are not always requested for tumour progression</span>.</p> 
  <p><span style="background-color:#ffa1a1">We found 27% K-Ras mutations in the whole series and a statistical association with M+ tumours (univariate analysis P =0.016; multivariate analysis P =0.019), suggesting K-Ras activation as an important determinant of extracolic tumour spread</span>. <span style="background-color:#ffeded">Gonzalez-Aguilera et al (2004) found increased K-Ras mutations in tumours with advanced Duke's stage (A 22%, B 27%, C 38% and D 33%), particularly when grouping M+ (46%) vs M? tumours (26%)</span>. <span style="background-color:#ffe3e3">Aberrant activation of K-Ras has been implicated in facilitating all aspects of a malignant phenotype, including proliferation, invasion and metastases by Ras effectors such as PIK3, Raf/MEK/ERK cascade and Rho GTPases</span>. <span style="background-color:#fff5f5">Recently, some authors proposed that epithelial cells with activated Ras signalling require the cooperation of other signalling pathway to became metastogenic ( Grunert et al , 2003 ) and the oncogenic Ras is thought to cooperates with several other proto-oncogenes such as p53 and p16INK4A ( Serrano et al , 1996 ; Aguirre et al , 2003 )</span>. <span style="background-color:#ffeded">This cooperation between Ras and other genes is likely to occur in CRC progression because, in our study, only 6% of tumours showed the exclusive presence of K-Ras mutation</span>. <span style="background-color:#ff9898">E-Cadherin promoter methylation was prevalent in the right colon (univariate analysis P =0.011; multivariate analysis P =0.007), so that coincidental K-Ras mutations and E-Cadherin methylation frequently occurred in proximal (27%) rather than left colon (5%) and rectum (8%) ( P &lt;0.001)</span>. <span style="background-color:#ffc5c5">Whether E-Cadherin methylation and K-Ras mutation cooperate in right side colonic carcinogenesis and progression have to be confirmed in larger series</span>. <span style="background-color:#ffc1c1">B-Raf was rarely found mutated in our cases and never in conjunction with K-Ras </span>. <span style="background-color:#ffe6e6">As previously noted ( Rajagopalan et al , 2002 ; Yuen et al , 2002 ), K-Ras and B-Raf mutations appear to be mutually exclusive, confirming previous suggestions that they have similar biological targets in the RAS-RAF-MEK-ERK-MAP kinase signalling pathway ( Yuen et al , 2002 )</span>. <span style="background-color:#ffd1d1">A small proportion of cases (10/202=5%) showed both K-Ras mutations and RASSF1A methylation; interestingly all these cases were M+ ( P =0.016)</span>. <span style="background-color:#ffffff">Whether alterations in both these genes may be able to confer a more aggressive phenotype remains to be established in larger series</span>.</p> 
  <p><span style="background-color:#ffeaea">In our study, p53 abnormalities were not prevalent in M+ tumours suggesting a limited role of p53 in CRC metastatisation</span>. <span style="background-color:#fff6f6">Different results were reported by Goh et al (1999) that used only SSCP to detect p53 mutations</span></p> 
  <p><span style="background-color:#ffe7e7">Among tumour suppressor genes showing DNA methylation, p16INK4A seems to play a major role in the metastogenic phenotype of primary CRCs</span>. <span style="background-color:#ffe2e2">Methylation was seen in 33% of the whole series and it was, like K-Ras mutation, significantly associated with a M+ phenotype (univariate analysis P =0.011; multivariate analysis P =0.001)</span>. <span style="background-color:#ffffff">A strong correlation between staging and p16INK4A methylation was found also by Yi et al (2001) ; loss of p16INK4A expression has been previously associated with lymph-node metastases ( Kim et al , 2005a ) and more advanced stage ( Jeong et al , 2005 )</span>. <span style="background-color:#ffffff">Altogether, these results suggest that p16INK4A methylation might link to a more malignant phenotype in CRC; interestingly Liang et al (1999) recently reported an association between p16INK4A methylation and shorter survival of CRC</span>. <span style="background-color:#ffdfdf">Coincidental alterations of K-Ras and p16INK4A were mainly found in M+ tumours (2/67 M? tumours vs 17/139 M+ tumours; P =0.034), suggesting that abnormalities in these pathways could cooperate for a more aggressive phenotype, as previously supported by Serrano et al (1997 )</span></p> 
  <p><span style="background-color:#ffecec">Another focus of this study was to examine the interactions between genetic and epigenetic alterations in the induction of a metastogenic phenotype</span>. <span style="background-color:#ffeded">Regardless the type of molecular abnormalities, tumours with three or more but not those with less than three, were significantly more prevalent in the group of M+ tumours ( P =0.023)</span>. <span style="background-color:#ffffff">This means that the genes under study can confer a more aggressive phenotype when molecular changes deregulate at least three of them</span>. <span style="background-color:#ffffff">This hypothesis is in keeping with a stepwise model of progression of CRC</span>. <span style="background-color:#fff6f6">Given that a fraction of M? CRCs (13%) already harbours three or more molecular changes, we are currently analysing this cohort to ascertain whether these cases will develop metachronous liver metastasis at an increase rate as compared to M? CRCs with &lt;3 molecular changes</span>. <span style="background-color:#ffcbcb">The group of M+ tumours showing three or more abnormal genes was characterised by a single genetic mutation (usually K-Ras ; 53%) and by two epigenetic alterations (equally affecting p16INK4A , RASSF1A and E-Cadherin )</span>. <span style="background-color:#fff9f9">Notably, Toyota et al (2000) found K-Ras mutations significantly prevalent in CRCs with the so called methylator phenotype (CIMP) compared with CIMP negative cases</span>. <span style="background-color:#ffe4e4">A stepwise increase in the number of methylated genes was observed with lesion progression through the stages of multistep colorectal carcinogenesis by Lee et al (2004) </span>. <span style="background-color:#ffecec">Our study showed that coincidental methylation of the three genes ( RASSF1A , E-Cadherin and p16INK4A ) was restricted to M+ tumours ( P =0.042)</span>. <span style="background-color:#fff3f3">It is unclear why advanced and M+ CRCs showed a high degree of methylation: perhaps advanced tumours inherited a major biological aggressiveness or were simply more likely to become methylated</span>. <span style="background-color:#ffb8b8">Notably, patients showing three methylated genes were also of older age (73.83 vs 65.60 years; P =0.017), in keeping with the suggestion put forwards by Toyota and Issa (1999 ) that age-related methylation might contribute to the sharp increase in cancer risk after the age of 60 years</span></p> 
  <p><span style="background-color:#ffe4e4">Interestingly, in the present study, younger age was statistically associated to M+ tumours</span>. <span style="background-color:#ffdddd">This is likely due to internal selection for surgical treatment, being the older age a limiting factor for radical surgical resection ( Leporrier et al , 2006 )</span></p> 
  <p><span style="background-color:#ffecec">In conclusion, analysis of a panel of genes provided to detect some genetic and epigenetic molecular differences between M+ and M? primary CRCs</span>. <span style="background-color:#ffcdcd">A set of genetic and epigenetic molecular abnormalities is a feature of primary M+ CRCs likely conferring the ability for tumour extracolic spread and determining markers for aggressive behaviour and potential therapeutic targets.</span></p> 
 </sec> 
 <!--xmat handling--> 
 <sec id="sup1" sec-type="supplementary-material"> 
  <h3>External data objects</h3> 
  <supplementary-material content-type="local-data" id="xob1"> 
   <h3>Supplementary Figure 1</h3> 
   <media mime-subtype="msword" mimetype="application" xlink:href="95-6603337x1.jpg"> 
    <label>Click here for supplemental data</label> 
   </media> 
  </supplementary-material> 
  <supplementary-material content-type="local-data" id="xob2"> 
   <h3>Supplementary Table 1</h3> 
   <media mime-subtype="msword" mimetype="application" xlink:href="95-6603337x2.doc"> 
    <label>Click here for supplemental data</label> 
   </media> 
  </supplementary-material> 
 </sec> 
 <back> 
  <ack> 
   <p>This paper was supported by 
    <italic>
      MURST 
    </italic> (COFIN 2003).</p> 
  </ack> 
  <notes notes-type="closenote"> 
   <p> 
    <xref ref-type="other" rid="sup1">
      Supplementary information 
    </xref> accompanies the paper on British Journal of Cancer website ( 
    <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/bjc">
      http://www.nature.com/bjc 
    </ext-link>)</p> 
  </notes> 
  <ref-list> 
   <ref id="bib1"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Aguirre 
       </surname> 
       <given-names>
         AJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bardeesy 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sinha 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lopez 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tuveson 
       </surname> 
       <given-names>
         DA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Horner 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Redston 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         DePinho 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma 
     </article-h3> 
     <source />Genes Dev 
     <year>
       2003 
     </year> 
     <volume>
       17 
     </volume> 
     <fpage>
       3112 
     </fpage> 
     <lpage>
       3126 
     </lpage> 
     <!--PubMed citation query: 'Genes Dev||17|3112||bib1|'--> 
     <pub-id pub-id-type="pmid">
       14681207 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib2"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Bazan 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Migliavacca 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zanna 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tubiolo 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Grassi 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Latteri 
       </surname> 
       <given-names>
         MA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         La Farina 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Albanese 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dardanoni 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Salerno 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tomasino 
       </surname> 
       <given-names>
         RM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Labianca 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gebbia 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Russo 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype 
     </article-h3> 
     <source />Ann Oncol 
     <year>
       2002 
     </year> 
     <volume>
       13 
     </volume> 
     <fpage>
       1438 
     </fpage> 
     <lpage>
       1446 
     </lpage> 
     <!--PubMed citation query: 'Ann Oncol||13|1438||bib2|'--> 
     <pub-id pub-id-type="pmid">
       12196370 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib3"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Chiang 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wu Chou 
       </surname> 
       <given-names>
         YH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ma 
       </surname> 
       <given-names>
         SC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         JR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes 
     </article-h3> 
     <source />Virchows Arch 
     <year>
       2004 
     </year> 
     <volume>
       445 
     </volume> 
     <fpage>
       465 
     </fpage> 
     <lpage>
       471 
     </lpage> 
     <!--PubMed citation query: 'Virchows Arch||445|465||bib3|'--> 
     <pub-id pub-id-type="pmid">
       15449054 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib4"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Cripps 
       </surname> 
       <given-names>
         KJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Purdie 
       </surname> 
       <given-names>
         CA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Carder 
       </surname> 
       <given-names>
         PJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         White 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Komine 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bird 
       </surname> 
       <given-names>
         CC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wyllie 
       </surname> 
       <given-names>
         AH 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A study of stabilisation of p53 protein versus point mutation in colorectal cancer 
     </article-h3> 
     <source />Oncogene 
     <year>
       1994 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       2739 
     </fpage> 
     <lpage>
       2743 
     </lpage> 
     <!--PubMed citation query: 'Oncogene||9|2739||bib4|'--> 
     <pub-id pub-id-type="pmid">
       8058340 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib5"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Dammann 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Schagdarsurengin 
       </surname> 
       <given-names>
         U 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Strunnikova 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rastetter 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Seidel 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tommasi 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pfeifer 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis 
     </article-h3> 
     <source />Histol Histopathol 
     <year>
       2003 
     </year> 
     <volume>
       18 
     </volume> 
     <fpage>
       665 
     </fpage> 
     <lpage>
       677 
     </lpage> 
     <!--PubMed citation query: 'Histol Histopathol||18|665||bib5|'--> 
     <pub-id pub-id-type="pmid">
       12647816 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib6"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Darwanto 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kitazawa 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Maeda 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kitazawa 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       MeCP2 and promoter methylation cooperatively regulate E-cadherin gene expression in colorectal carcinoma 
     </article-h3> 
     <source />Cancer Sci 
     <year>
       2003 
     </year> 
     <volume>
       94 
     </volume> 
     <fpage>
       442 
     </fpage> 
     <lpage>
       447 
     </lpage> 
     <!--PubMed citation query: 'Cancer Sci||94|442||bib6|'--> 
     <pub-id pub-id-type="pmid">
       12824891 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib7"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Davies 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bignell 
       </surname> 
       <given-names>
         GR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cox 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stephens 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Edkins 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Clegg 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Teague 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Woffendin 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Garnett 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bottomley 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davis 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dicks 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ewing 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Floyd 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gray 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hall 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hawes 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hughes 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kosmidou 
       </surname> 
       <given-names>
         V 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Menzies 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mould 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parker 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stevens 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Watt 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hooper 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wilson 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jayatilake 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gusterson 
       </surname> 
       <given-names>
         BA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cooper 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shipley 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hargrave 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pritchard-Jones 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Maitland 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chenevix-Trench 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Riggins 
       </surname> 
       <given-names>
         GJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bigner 
       </surname> 
       <given-names>
         DD 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Palmieri 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cossu 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Flanagan 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Nicholson 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ho 
       </surname> 
       <given-names>
         JW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Leung 
       </surname> 
       <given-names>
         SY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yuen 
       </surname> 
       <given-names>
         ST 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weber 
       </surname> 
       <given-names>
         BL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Seigler 
       </surname> 
       <given-names>
         HF 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Darrow 
       </surname> 
       <given-names>
         TL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Paterson 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marais 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Marshall 
       </surname> 
       <given-names>
         CJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wooster 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stratton 
       </surname> 
       <given-names>
         MR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Futreal 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutations of the BRAF gene in human cancer 
     </article-h3> 
     <source />Nature 
     <year>
       2002 
     </year> 
     <volume>
       417 
     </volume> 
     <fpage>
       949 
     </fpage> 
     <lpage>
       954 
     </lpage> 
     <!--PubMed citation query: 'Nature||417|949||bib7|'--> 
     <pub-id pub-id-type="pmid">
       12068308 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib8"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         de la Chapelle 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Genetic predisposition to colorectal cancer 
     </article-h3> 
     <source />Nat Rev Cancer 
     <year>
       2004 
     </year> 
     <volume>
       4 
     </volume> 
     <fpage>
       769 
     </fpage> 
     <lpage>
       780 
     </lpage> 
     <!--PubMed citation query: 'Nat Rev Cancer||4|769||bib8|'--> 
     <pub-id pub-id-type="pmid">
       15510158 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib9"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Fearon 
       </surname> 
       <given-names>
         ER 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vogelstein 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A genetic model for colorectal tumorigenesis 
     </article-h3> 
     <source />Cell 
     <year>
       1990 
     </year> 
     <volume>
       61 
     </volume> 
     <fpage>
       759 
     </fpage> 
     <lpage>
       767 
     </lpage> 
     <!--PubMed citation query: 'Cell||61|759||bib9|'--> 
     <pub-id pub-id-type="pmid">
       2188735 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib10"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Garinis 
       </surname> 
       <given-names>
         GA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Menounos 
       </surname> 
       <given-names>
         PG 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Spanakis 
       </surname> 
       <given-names>
         NE 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Papadopoulos 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Karavitis 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Parassi 
       </surname> 
       <given-names>
         I 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Christeli 
       </surname> 
       <given-names>
         E 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Patrinos 
       </surname> 
       <given-names>
         GP 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Manolis 
       </surname> 
       <given-names>
         EN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Peros 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas 
     </article-h3> 
     <source />J Pathol 
     <year>
       2002 
     </year> 
     <volume>
       198 
     </volume> 
     <fpage>
       442 
     </fpage> 
     <lpage>
       449 
     </lpage> 
     <!--PubMed citation query: 'J Pathol||198|442||bib10|'--> 
     <pub-id pub-id-type="pmid">
       12434413 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib11"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Giehl 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Oncogenic Ras in tumour progression and metastasis 
     </article-h3> 
     <source />Biol Chem 
     <year>
       2005 
     </year> 
     <volume>
       386 
     </volume> 
     <fpage>
       193 
     </fpage> 
     <lpage>
       205 
     </lpage> 
     <!--PubMed citation query: 'Biol Chem||386|193||bib11|'--> 
     <pub-id pub-id-type="pmid">
       15843165 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib12"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Goh 
       </surname> 
       <given-names>
         HS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Elnatan 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Low 
       </surname> 
       <given-names>
         CH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Smith 
       </surname> 
       <given-names>
         DR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       p53 point mutation and survival in colorectal cancer patients: effect of disease dissemination and tumour location 
     </article-h3> 
     <source />Int J Oncol 
     <year>
       1999 
     </year> 
     <volume>
       15 
     </volume> 
     <fpage>
       491 
     </fpage> 
     <lpage>
       498 
     </lpage> 
     <!--PubMed citation query: 'Int J Oncol||15|491||bib12|'--> 
     <pub-id pub-id-type="pmid">
       10427130 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib13"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Gonzalez-Aguilera 
       </surname> 
       <given-names>
         JJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Oliart 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Azcoita 
       </surname> 
       <given-names>
         MM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fernandez-Peralta 
       </surname> 
       <given-names>
         AM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer 
     </article-h3> 
     <source />Am J Clin Oncol 
     <year>
       2004 
     </year> 
     <volume>
       27 
     </volume> 
     <fpage>
       39 
     </fpage> 
     <lpage>
       45 
     </lpage> 
     <!--PubMed citation query: 'Am J Clin Oncol||27|39||bib13|'--> 
     <pub-id pub-id-type="pmid">
       14758132 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib14"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Grunert 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Jechlinger 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Beug 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis 
     </article-h3> 
     <source />Nat Rev Mol Cell Biol 
     <year>
       2003 
     </year> 
     <volume>
       4 
     </volume> 
     <fpage>
       657 
     </fpage> 
     <lpage>
       665 
     </lpage> 
     <!--PubMed citation query: 'Nat Rev Mol Cell Biol||4|657||bib14|'--> 
     <pub-id pub-id-type="pmid">
       12923528 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib15"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Jeong 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Park 
       </surname> 
       <given-names>
         YN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Park 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yoon 
       </surname> 
       <given-names>
         DS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chi 
       </surname> 
       <given-names>
         HS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         BR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer 
     </article-h3> 
     <source />Yonsei Med J 
     <year>
       2005 
     </year> 
     <volume>
       46 
     </volume> 
     <fpage>
       519 
     </fpage> 
     <lpage>
       525 
     </lpage> 
     <!--PubMed citation query: 'Yonsei Med J||46|519||bib15|'--> 
     <pub-id pub-id-type="pmid">
       16127777 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib16"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kamb 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shattuck-Eidens 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Eeles 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Liu 
       </surname> 
       <given-names>
         Q 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gruis 
       </surname> 
       <given-names>
         NA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ding 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hussey 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tran 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Miki 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Weaver-Feldhaus 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus 
     </article-h3> 
     <source />Nat Genet 
     <year>
       1994 
     </year> 
     <volume>
       8 
     </volume> 
     <fpage>
       23 
     </fpage> 
     <lpage>
       26 
     </lpage> 
     <!--PubMed citation query: 'Nat Genet||8|23||bib16|'--> 
     <pub-id pub-id-type="pmid">
       7987388 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib17"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         BN 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yamamoto 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ikeda 
       </surname> 
       <given-names>
         K 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Damdinsuren 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sugita 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ngan 
       </surname> 
       <given-names>
         CY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Fujie 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ogawa 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hata 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ikeda 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ohue 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sekimoto 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Monden 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Matsuura 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Monden 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues 
     </article-h3> 
     <source />Int J Oncol 
     <year>
       2005a 
     </year> 
     <volume>
       26 
     </volume> 
     <fpage>
       1217 
     </fpage> 
     <lpage>
       1226 
     </lpage> 
     <!--PubMed citation query: 'Int J Oncol||26|1217||bib17|'--> 
     <pub-id pub-id-type="pmid">
       15809712 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib18"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         HC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Roh 
       </surname> 
       <given-names>
         SA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ga 
       </surname> 
       <given-names>
         IH 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yu 
       </surname> 
       <given-names>
         CS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer 
     </article-h3> 
     <source />J Gastroenterol Hepatol 
     <year>
       2005b 
     </year> 
     <volume>
       20 
     </volume> 
     <fpage>
       1920 
     </fpage> 
     <lpage>
       1926 
     </lpage> 
     <!--PubMed citation query: 'J Gastroenterol Hepatol||20|1920||bib18|'--> 
     <pub-id pub-id-type="pmid">
       16336454 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib19"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Kolch 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions 
     </article-h3> 
     <source />Biochem J 
     <year>
       2000 
     </year> 
     <volume>
       351 
     </volume> 
     <fpage>
       289 
     </fpage> 
     <lpage>
       305 
     </lpage> 
     <!--PubMed citation query: 'Biochem J||351|289||bib19|'--> 
     <pub-id pub-id-type="pmid">
       11023813 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib20"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hwang 
       </surname> 
       <given-names>
         KS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         HJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kang 
       </surname> 
       <given-names>
         GH 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia 
     </article-h3> 
     <source />Lab Invest 
     <year>
       2004 
     </year> 
     <volume>
       84 
     </volume> 
     <fpage>
       884 
     </fpage> 
     <lpage>
       893 
     </lpage> 
     <!--PubMed citation query: 'Lab Invest||84|884||bib20|'--> 
     <pub-id pub-id-type="pmid">
       15122305 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib21"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Leporrier 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Maurel 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chiche 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bara 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Segol 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Launoy 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer 
     </article-h3> 
     <source />Br J Surg 
     <year>
       2006 
     </year> 
     <volume>
       93 
     </volume> 
     <fpage>
       465 
     </fpage> 
     <lpage>
       474 
     </lpage> 
     <!--PubMed citation query: 'Br J Surg||93|465||bib21|'--> 
     <pub-id pub-id-type="pmid">
       16523446 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib22"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Liang 
       </surname> 
       <given-names>
         JT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chang 
       </surname> 
       <given-names>
         KJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         JC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         CC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cheng 
       </surname> 
       <given-names>
         YM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Hsu 
       </surname> 
       <given-names>
         HC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wu 
       </surname> 
       <given-names>
         MS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wang 
       </surname> 
       <given-names>
         SM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lin 
       </surname> 
       <given-names>
         JT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cheng 
       </surname> 
       <given-names>
         AL 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival 
     </article-h3> 
     <source />Oncology 
     <year>
       1999 
     </year> 
     <volume>
       57 
     </volume> 
     <fpage>
       149 
     </fpage> 
     <lpage>
       156 
     </lpage> 
     <!--PubMed citation query: 'Oncology||57|149||bib22|'--> 
     <pub-id pub-id-type="pmid">
       10461063 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib23"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Pizzi 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Azzoni 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bottarelli 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Campanini 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         D'Adda 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Pasquali 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rossi 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Rindi 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bordi 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours 
     </article-h3> 
     <source />J Pathol 
     <year>
       2005 
     </year> 
     <volume>
       206 
     </volume> 
     <fpage>
       409 
     </fpage> 
     <lpage>
       416 
     </lpage> 
     <!--PubMed citation query: 'J Pathol||206|409||bib23|'--> 
     <pub-id pub-id-type="pmid">
       15887288 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib24"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Pollock 
       </surname> 
       <given-names>
         CB 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Shirasawa 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Sasazuki 
       </surname> 
       <given-names>
         T 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kolch 
       </surname> 
       <given-names>
         W 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dhillon 
       </surname> 
       <given-names>
         AS 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2005 
     </year> 
     <volume>
       65 
     </volume> 
     <fpage>
       1244 
     </fpage> 
     <lpage>
       1250 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||65|1244||bib24|'--> 
     <pub-id pub-id-type="pmid">
       15735008 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib25"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Rajagopalan 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bardelli 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lengauer 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kinzler 
       </surname> 
       <given-names>
         KW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Vogelstein 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Velculescu 
       </surname> 
       <given-names>
         VE 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status 
     </article-h3> 
     <source />Nature 
     <year>
       2002 
     </year> 
     <volume>
       418 
     </volume> 
     <fpage>
       934 
     </fpage> 
     <!--PubMed citation query: 'Nature||418|934||bib25|'--> 
     <pub-id pub-id-type="pmid">
       12198537 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib26"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Remvikos 
       </surname> 
       <given-names>
         Y 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Laurent-Puig 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Salmon 
       </surname> 
       <given-names>
         RJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Frelat 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Dutrillaux 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Thomas 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       1990 
     </year> 
     <volume>
       45 
     </volume> 
     <fpage>
       450 
     </fpage> 
     <lpage>
       456 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||45|450||bib26|'--> 
     <pub-id pub-id-type="pmid">
       2137812 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib27"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Roncalli 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bianchi 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bruni 
       </surname> 
       <given-names>
         B 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Laghi 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Destro 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Di Gioia 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Gennari 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tommasini 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Malesci 
       </surname> 
       <given-names>
         A 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Coggi 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma 
     </article-h3> 
     <source />Hepatology 
     <year>
       2002 
     </year> 
     <volume>
       36 
     </volume> 
     <fpage>
       427 
     </fpage> 
     <lpage>
       432 
     </lpage> 
     <!--PubMed citation query: 'Hepatology||36|427||bib27|'--> 
     <pub-id pub-id-type="pmid">
       12143052 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib28"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Serrano 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lee 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chin 
       </surname> 
       <given-names>
         L 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cordon-Cardo 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Beach 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         DePinho 
       </surname> 
       <given-names>
         RA 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Role of the INK4a locus in tumor suppression and cell mortality 
     </article-h3> 
     <source />Cell 
     <year>
       1996 
     </year> 
     <volume>
       85 
     </volume> 
     <fpage>
       27 
     </fpage> 
     <lpage>
       37 
     </lpage> 
     <!--PubMed citation query: 'Cell||85|27||bib28|'--> 
     <pub-id pub-id-type="pmid">
       8620534 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib29"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Serrano 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lin 
       </surname> 
       <given-names>
         AW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         McCurrach 
       </surname> 
       <given-names>
         ME 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Beach 
       </surname> 
       <given-names>
         D 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lowe 
       </surname> 
       <given-names>
         SW 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Oncogenic 
      <italic>
        ras 
      </italic> provokes premature cell senescence associated with accumulation of p53 and p16 
      <sup>INK4a</sup> 
     </article-h3> 
     <source />Cell 
     <year>
       1997 
     </year> 
     <volume>
       88 
     </volume> 
     <fpage>
       593 
     </fpage> 
     <lpage>
       602 
     </lpage> 
     <!--PubMed citation query: 'Cell||88|593||bib29|'--> 
     <pub-id pub-id-type="pmid">
       9054499 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib30"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Smith 
       </surname> 
       <given-names>
         G 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Carey 
       </surname> 
       <given-names>
         FA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Beattie 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wilkie 
       </surname> 
       <given-names>
         MJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Lightfoot 
       </surname> 
       <given-names>
         TJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Coxhead 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Garner 
       </surname> 
       <given-names>
         RC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Steele 
       </surname> 
       <given-names>
         RJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wolf 
       </surname> 
       <given-names>
         CR 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Mutations in APC, Kirsten-ras, and p53 ? alternative genetic pathways to colorectal cancer 
     </article-h3> 
     <source />Proc Natl Acad Sci USA 
     <year>
       2002 
     </year> 
     <volume>
       99 
     </volume> 
     <fpage>
       9433 
     </fpage> 
     <lpage>
       9438 
     </lpage> 
     <!--PubMed citation query: 'Proc Natl Acad Sci USA||99|9433||bib30|'--> 
    </citation> 
   </ref> 
   <ref id="bib31"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Takeichi 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Morphogenetic roles of classic cadherins 
     </article-h3> 
     <source />Curr Opin Cell Biol 
     <year>
       1995 
     </year> 
     <volume>
       7 
     </volume> 
     <fpage>
       619 
     </fpage> 
     <lpage>
       627 
     </lpage> 
     <!--PubMed citation query: 'Curr Opin Cell Biol||7|619||bib31|'--> 
     <pub-id pub-id-type="pmid">
       8573335 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib32"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Toyota 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Issa 
       </surname> 
       <given-names>
         JP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       CpG island methylator phenotype in aging and cancer 
     </article-h3> 
     <source />Semin Cancer Biol 
     <year>
       1999 
     </year> 
     <volume>
       9 
     </volume> 
     <fpage>
       349 
     </fpage> 
     <lpage>
       357 
     </lpage> 
     <!--PubMed citation query: 'Semin Cancer Biol||9|349||bib32|'--> 
     <pub-id pub-id-type="pmid">
       10547343 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib33"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Toyota 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ohe-Toyota 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ahuja 
       </surname> 
       <given-names>
         N 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Issa 
       </surname> 
       <given-names>
         JP 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype 
     </article-h3> 
     <source />Proc Natl Acad Sci USA 
     <year>
       2000 
     </year> 
     <volume>
       97 
     </volume> 
     <fpage>
       710 
     </fpage> 
     <lpage>
       715 
     </lpage> 
     <!--PubMed citation query: 'Proc Natl Acad Sci USA||97|710||bib33|'--> 
    </citation> 
   </ref> 
   <ref id="bib34"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Wheeler 
       </surname> 
       <given-names>
         JM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Kim 
       </surname> 
       <given-names>
         HC 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Efstathiou 
       </surname> 
       <given-names>
         JA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ilyas 
       </surname> 
       <given-names>
         M 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Mortensen 
       </surname> 
       <given-names>
         NJ 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bodmer 
       </surname> 
       <given-names>
         WF 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer 
     </article-h3> 
     <source />Gut 
     <year>
       2001 
     </year> 
     <volume>
       48 
     </volume> 
     <fpage>
       367 
     </fpage> 
     <lpage>
       371 
     </lpage> 
     <!--PubMed citation query: 'Gut||48|367||bib34|'--> 
     <pub-id pub-id-type="pmid">
       11171827 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib35"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Yi 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wang 
       </surname> 
       <given-names>
         ZW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cang 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chen 
       </surname> 
       <given-names>
         YY 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Zhao 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Yu 
       </surname> 
       <given-names>
         BM 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tang 
       </surname> 
       <given-names>
         XM 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       p16 gene methylation in colorectal cancers associated with Duke's staging 
     </article-h3> 
     <source />World J Gastroenterol 
     <year>
       2001 
     </year> 
     <volume>
       7 
     </volume> 
     <fpage>
       722 
     </fpage> 
     <lpage>
       725 
     </lpage> 
     <!--PubMed citation query: 'World J Gastroenterol||7|722||bib35|'--> 
     <pub-id pub-id-type="pmid">
       11819863 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib36"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Yuen 
       </surname> 
       <given-names>
         ST 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Davies 
       </surname> 
       <given-names>
         H 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chan 
       </surname> 
       <given-names>
         TL 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Ho 
       </surname> 
       <given-names>
         JW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bignell 
       </surname> 
       <given-names>
         GR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Cox 
       </surname> 
       <given-names>
         C 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stephens 
       </surname> 
       <given-names>
         P 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Edkins 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Tsui 
       </surname> 
       <given-names>
         WW 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Chan 
       </surname> 
       <given-names>
         AS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Futreal 
       </surname> 
       <given-names>
         PA 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Stratton 
       </surname> 
       <given-names>
         MR 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Wooster 
       </surname> 
       <given-names>
         R 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Leung 
       </surname> 
       <given-names>
         SY 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia 
     </article-h3> 
     <source />Cancer Res 
     <year>
       2002 
     </year> 
     <volume>
       62 
     </volume> 
     <fpage>
       6451 
     </fpage> 
     <lpage>
       6455 
     </lpage> 
     <!--PubMed citation query: 'Cancer Res||62|6451||bib36|'--> 
     <pub-id pub-id-type="pmid">
       12438234 
     </pub-id> 
    </citation> 
   </ref> 
   <ref id="bib37"> 
    <citation citation-type="journal"> 
     <person-group person-group-type="author"> 
      <name> 
       <surname>
         Zhang 
       </surname> 
       <given-names>
         JS 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Caplin 
       </surname> 
       <given-names>
         S 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Bosman 
       </surname> 
       <given-names>
         FT 
       </given-names> 
      </name> 
      <name> 
       <surname>
         Benhattar 
       </surname> 
       <given-names>
         J 
       </given-names> 
      </name> 
     </person-group> 
     <article-h3>
       Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph-node metastases 
     </article-h3> 
     <source />Int J Cancer 
     <year>
       1997 
     </year> 
     <volume>
       70 
     </volume> 
     <fpage>
       674 
     </fpage> 
     <lpage>
       678 
     </lpage> 
     <!--PubMed citation query: 'Int J Cancer||70|674||bib37|'--> 
     <pub-id pub-id-type="pmid">
       9096648 
     </pub-id> 
    </citation> 
   </ref> 
  </ref-list> 
 </back> 
 <floats-wrap> 
  <table-wrap id="tbl1" position="float"> 
   <label>Table 1</label> 
   <p content-type="table-h3">Clinico-pathological features of the series under study as related to M+ and M? tumours</p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="center" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         All patients 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         M? 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         M+ 
       </bold> </th> 
      <th align="center" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          n 
        </italic>=202 (100%) 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          n 
        </italic>=72 (100%) 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          n 
        </italic>=130 (100%) 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         Univariate analysis 
       </bold> </th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">Age (years?s.d.)</td> 
      <td align="center" charoff="50" valign="top">66.05?11.66</td> 
      <td align="center" charoff="50" valign="top">69.40?11.44</td> 
      <td align="center" charoff="50" valign="top">64.2?11.40</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.002</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="5" valign="top"> 
       <italic>
         Sex 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?F</td> 
      <td align="center" charoff="50" valign="top">81 (40%)</td> 
      <td align="center" charoff="50" valign="top">26 (36%)</td> 
      <td align="center" charoff="50" valign="top">55 (42%)</td> 
      <td align="center" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M</td> 
      <td align="center" charoff="50" valign="top">121 (60%)</td> 
      <td align="center" charoff="50" valign="top">46 (64%)</td> 
      <td align="center" charoff="50" valign="top">75 (58%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="5" valign="top"> 
       <italic>
         Location 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?R</td> 
      <td align="center" charoff="50" valign="top">71 (35%)</td> 
      <td align="center" charoff="50" valign="top">23 (32%)</td> 
      <td align="center" charoff="50" valign="top">48 (37%)</td> 
      <td align="center" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?L</td> 
      <td align="center" charoff="50" valign="top">78 (39%)</td> 
      <td align="center" charoff="50" valign="top">30 (42%)</td> 
      <td align="center" charoff="50" valign="top">48 (37%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?Re</td> 
      <td align="center" charoff="50" valign="top">53 (26%)</td> 
      <td align="center" charoff="50" valign="top">19 (26%)</td> 
      <td align="center" charoff="50" valign="top">34 (26%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="5" valign="top"> 
       <italic>
         Grading 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G1</td> 
      <td align="center" charoff="50" valign="top">14 (7%)</td> 
      <td align="center" charoff="50" valign="top">9 (13%)</td> 
      <td align="center" charoff="50" valign="top">5 (4%)</td> 
      <td align="center" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.069</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G2</td> 
      <td align="center" charoff="50" valign="top">145 (72%)</td> 
      <td align="center" charoff="50" valign="top">47 (65%)</td> 
      <td align="center" charoff="50" valign="top">98 (75%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G3</td> 
      <td align="center" charoff="50" valign="top">43 (21%)</td> 
      <td align="center" charoff="50" valign="top">16 (22%)</td> 
      <td align="center" charoff="50" valign="top">27 (21%)</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote1"> 
     <label></label> 
     <p>F=female; L=left side; M=male; M+=metastatic tumours; M?=nonmetastatic tumours; NS=not significant; R=right side; Re=rectum; s.d.=standard deviation.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl2a" position="float"> 
   <label>Table 2a</label> 
   <p content-type="table-h3">Genetic alterations: mutation frequencies for 
    <italic>
      K-Ras 
    </italic>, 
    <italic>
      B-Raf 
    </italic> and 
    <italic>
      p53 
    </italic> </p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         All cases 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          K-Ras 
        </italic> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          B-Raf 
        </italic> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          p53 
        </italic> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">All patients</td> 
      <td align="center" charoff="50" valign="top">202</td> 
      <td align="center" charoff="50" valign="top">54 (27%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">7 (3%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">65 (32%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Age (years?s.d.)</td> 
      <td align="center" charoff="50" valign="top">66.05?11.66</td> 
      <td align="center" charoff="50" valign="top">67.16?11.56</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">64.42?13.50</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">65.23?12.17</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Sex 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?F</td> 
      <td align="center" charoff="50" valign="top">81</td> 
      <td align="center" charoff="50" valign="top">24 (30%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">2 (2%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">22 (27%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M</td> 
      <td align="center" charoff="50" valign="top">121</td> 
      <td align="center" charoff="50" valign="top">30 (25%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">5 (4%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">43 (35%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Tumour 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M?</td> 
      <td align="center" charoff="50" valign="top">72</td> 
      <td align="center" charoff="50" valign="top">12 (17%)</td> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.016</td> 
      <td align="center" charoff="50" valign="top">1 (1%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">26 (36%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M+</td> 
      <td align="center" charoff="50" valign="top">130</td> 
      <td align="center" charoff="50" valign="top">42 (32%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">6 (5%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">39 (23%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Location 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?R</td> 
      <td align="center" charoff="50" valign="top">71</td> 
      <td align="center" charoff="50" valign="top">25 (35%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">5 (7%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">23 (32%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?L</td> 
      <td align="center" charoff="50" valign="top">78</td> 
      <td align="center" charoff="50" valign="top">15 (19%)</td> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.088</td> 
      <td align="center" charoff="50" valign="top">1 (1%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">23 (29%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?Re</td> 
      <td align="center" charoff="50" valign="top">53</td> 
      <td align="center" charoff="50" valign="top">14 (26%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">1 (2%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">19 (36%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Grading 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G1</td> 
      <td align="center" charoff="50" valign="top">14</td> 
      <td align="center" charoff="50" valign="top">5 (36%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">?</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">4 (29%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G2</td> 
      <td align="center" charoff="50" valign="top">145</td> 
      <td align="center" charoff="50" valign="top">38 (26%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">4 (3%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">48 (33%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G3</td> 
      <td align="center" charoff="50" valign="top">43</td> 
      <td align="center" charoff="50" valign="top">11 (26%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">3 (7%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">13 (30%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote2"> 
     <label></label> 
     <p>F=female; L=left side; M=male; M+=metastatic tumours; M?=nonmetastatic tumours; NS=not significant; R=right side; Re=rectum; s.d.=standard deviation.</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
  <table-wrap id="tbl2b" position="float"> 
   <label>Table 2b</label> 
   <p content-type="table-h3">Epigenetic alterations: promoter methylation frequencies for 
    <italic>
      RASSF1A 
    </italic>, 
    <italic>
      E-Cadherin 
    </italic> and 
    <italic>
      p16INK4A 
    </italic> </p> 
   <table border="1" frame="hsides" rules="groups" width="85%"> 
    <colgroup> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
     <col align="center" /> 
     <col align="left" /> 
    </colgroup> 
    <thead valign="bottom"> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         All cases 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          RASSF1A 
        </italic> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         E-CAD 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold> 
        <italic>
          p16INK4A 
        </italic> 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
     <tr> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. 
       </bold> </th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
      <th align="center" charoff="50" valign="top"> 
       <bold>
         No. (%) 
       </bold> </th> 
      <th align="left" charoff="50" valign="top">&nbsp;</th> 
     </tr> 
    </thead> 
    <tbody valign="top"> 
     <tr> 
      <td align="left" charoff="50" valign="top">All patients</td> 
      <td align="center" charoff="50" valign="top">202</td> 
      <td align="center" charoff="50" valign="top">40 (20%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">88 (44%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">67 (33%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">Age (years?s.d.)</td> 
      <td align="center" charoff="50" valign="top">66.05?11.66</td> 
      <td align="center" charoff="50" valign="top">66.75?12.52</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">68.86?10.63<sup>a</sup></td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">67.25?12.02</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Sex 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?F</td> 
      <td align="center" charoff="50" valign="top">81</td> 
      <td align="center" charoff="50" valign="top">18 (22%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">34 (42%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">27 (33%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M</td> 
      <td align="center" charoff="50" valign="top">121</td> 
      <td align="center" charoff="50" valign="top">22 (18%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">54 (45%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">40 (33%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Tumour 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M?</td> 
      <td align="center" charoff="50" valign="top">72</td> 
      <td align="center" charoff="50" valign="top">8 (11%)</td> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.021</td> 
      <td align="center" charoff="50" valign="top">34 (47%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">12 (17%)</td> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>&lt;0.001</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?M+</td> 
      <td align="center" charoff="50" valign="top">130</td> 
      <td align="center" charoff="50" valign="top">32 (25%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">54 (41%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">55(42%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Location 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?R</td> 
      <td align="center" charoff="50" valign="top">71</td> 
      <td align="center" charoff="50" valign="top">14 (20%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">41 (58%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">24 (34%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?L</td> 
      <td align="center" charoff="50" valign="top">78</td> 
      <td align="center" charoff="50" valign="top">15 (19%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">29 (37%)</td> 
      <td align="left" charoff="50" valign="top"> 
       <italic>
         P 
       </italic>=0.011</td> 
      <td align="center" charoff="50" valign="top">27 (35%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?Re</td> 
      <td align="center" charoff="50" valign="top">53</td> 
      <td align="center" charoff="50" valign="top">11 (21%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">18 (34%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">16 (30%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">&nbsp;</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" colspan="8" valign="top"> 
       <italic>
         Grading 
       </italic> </td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G1</td> 
      <td align="center" charoff="50" valign="top">14</td> 
      <td align="center" charoff="50" valign="top">3 (21%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">7 (50%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">5 (36%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G2</td> 
      <td align="center" charoff="50" valign="top">145</td> 
      <td align="center" charoff="50" valign="top">28 (19%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">65 (45%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
      <td align="center" charoff="50" valign="top">48 (33%)</td> 
      <td align="left" charoff="50" valign="top">NS</td> 
     </tr> 
     <tr> 
      <td align="left" charoff="50" valign="top">?G3</td> 
      <td align="center" charoff="50" valign="top">43</td> 
      <td align="center" charoff="50" valign="top">9 (21%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">16 (37%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
      <td align="center" charoff="50" valign="top">14 (33%)</td> 
      <td align="left" charoff="50" valign="top">&nbsp;</td> 
     </tr> 
    </tbody> 
   </table> 
   <table-wrap-foot> 
    <fn id="tbfnote3"> 
     <label></label> 
     <p>F=female; L=left side; M=male; M+=metastatic tumours; M?=nonmetastatic tumours; NS=not significant; R=right side; Re=rectum; s.d.=standard deviation.</p> 
    </fn> 
    <fn id="tbfnote4"> 
     <label>a</label> 
     <p>Methylated 
      <italic>
        vs 
      </italic> nonmethylated=68.86?10.63 
      <italic>
        vs 
      </italic> 63.89?11.99 ( 
      <italic>
        P 
      </italic>=0.002).</p> 
    </fn> 
   </table-wrap-foot> 
  </table-wrap> 
 </floats-wrap> 
</article>